Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis…
Search
Have an existing account?
Sign In
Tag: US10806X1028